Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1–uninfected adult participants in the US

This publication has 26 references indexed in Scilit:

• Selected HIV-1 Env Trimeric Formulations Act as Potent Immunogens in a Rabbit Vaccination Model
  PLOS ONE, 2013
• Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial
  New England Journal of Medicine, 2012
• Magnitude and Breadth of a Nonprotective Neutralizing Antibody Response in an Efficacy Trial of a Candidate HIV‐1 gp120 Vaccine
  The Journal of Infectious Diseases, 2010
• Vaccine-Induced HIV Seropositivity/Reactivity in Noninfected HIV Vaccine Recipients
  JAMA, 2010
• Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
  New England Journal of Medicine, 2009
• Utilization of Immunoglobulin G Fc Receptors by Human Immunodeficiency Virus Type 1: a Specific Role for Antibodies against the Membrane-Proximal External Region of gp41
  Journal of Virology, 2009
• Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques
  Nature Medicine, 2009
• Fc receptor but not complement binding is important in antibody protection against HIV
  Nature, 2007
• Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination
  Journal of Immunological Methods, 2007
• Randomized, Double‐Blind, Placebo‐Controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV‐1 Vaccine among Injection Drug Users in Bangkok, Thailand
  The Journal of Infectious Diseases, 2006